What the studies show
Weekly dosing produced sustained multi-fold GH increases and IGF-1 elevations over weeks in healthy adults — a large, reproducible effect on the marker.
Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.
- 1Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults.J Clin Endocrinol Metab, 2006;91:799–805The early-phase human pharmacology; no outcome endpoints.
In context
CJC-1295 is a modified growth-hormone-releasing hormone fragment engineered to bind albumin so that it lasts days rather than minutes. Early human trials showed substantial, sustained rises in growth hormone and IGF-1 with weekly dosing. Development was discontinued and no trial has measured whether that translates into any clinical outcome. It is not approved anywhere and is banned in sport.
CJC-1295 is not approved. Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is CJC-1295 proven to help with growth hormone / IGF-1 elevation?
What studies are behind the grade?
Is CJC-1295 approved for this?
Other outcomes for CJC-1295
- DBody compositionNone
- DAny clinical outcomeNone
- CSafety in humansadverseEarly-phase only
Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →